olprinone has been researched along with Disease Exacerbation in 2 studies
olprinone: RN refers to HCl; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " The authors examined whether olprinone, a phosphodiesterase III inhibitor, protected functional and structural integrity of gut mucosa against acute progressive hypoxia." | 7.72 | Olprinone, a phosphodiesterase III inhibitor, reduces gut mucosal injury and portal endotoxin level during acute hypoxia in rabbits. ( Ai, K; Kosugi, S; Kotake, Y; Morisaki, H; Satoh, T; Serita, R; Takeda, J; Yamamoto, M, 2003) |
| "Milrinone-treated patients with ischemic heart disease and chronic kidney disease (CKD) at stage ≥ 4 presented with greater incidence of MACCE (log rank; P < 0." | 5.56 | Comparing the effects of milrinone and olprinone in patients with congestive heart failure. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Nakanishi, R; Oka, T; Watanabe, I, 2020) |
| " The authors examined whether olprinone, a phosphodiesterase III inhibitor, protected functional and structural integrity of gut mucosa against acute progressive hypoxia." | 3.72 | Olprinone, a phosphodiesterase III inhibitor, reduces gut mucosal injury and portal endotoxin level during acute hypoxia in rabbits. ( Ai, K; Kosugi, S; Kotake, Y; Morisaki, H; Satoh, T; Serita, R; Takeda, J; Yamamoto, M, 2003) |
| "Milrinone-treated patients with ischemic heart disease and chronic kidney disease (CKD) at stage ≥ 4 presented with greater incidence of MACCE (log rank; P < 0." | 1.56 | Comparing the effects of milrinone and olprinone in patients with congestive heart failure. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Nakanishi, R; Oka, T; Watanabe, I, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dobashi, S | 1 |
| Watanabe, I | 1 |
| Nakanishi, R | 1 |
| Hisatake, S | 1 |
| Kiuchi, S | 1 |
| Kabuki, T | 1 |
| Oka, T | 1 |
| Fujii, T | 1 |
| Ikeda, T | 1 |
| Satoh, T | 1 |
| Morisaki, H | 1 |
| Ai, K | 1 |
| Kosugi, S | 1 |
| Yamamoto, M | 1 |
| Serita, R | 1 |
| Kotake, Y | 1 |
| Takeda, J | 1 |
2 other studies available for olprinone and Disease Exacerbation
| Article | Year |
|---|---|
Comparing the effects of milrinone and olprinone in patients with congestive heart failure.
Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Disease Progression; Female; Heart Failure; Hospitaliza | 2020 |
Olprinone, a phosphodiesterase III inhibitor, reduces gut mucosal injury and portal endotoxin level during acute hypoxia in rabbits.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acute Disease; Animals; Carbon Dioxide; Cyclic Nucleotide Phosp | 2003 |